Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study). 26. Juli 2018 Wehmeyer, J., Zaiss, M., Losem, C., Schmitz, S., Niemeier, B., Harde, J., Hannig, C.V., Harich, H.-D., Müller, J., Klausmann, M., Tessen, H.W., Potthoff, K., 2018. Eur J Haematol 101(6), 766–773. doi:10.1111/ejh.13160 Abstract Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL. Boegemann, M., Bedke, J., Schostak, M., Welslau, M., Hering-Schubert, T., Wolf, T., Schleicher, J., Ehness, R., Klein, D., Medinger, T., Goebell, P., 2018. Oncol Res… Weiterlesen Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment-Analyses from the German clinical RCC-Registry. Goebell, P.J., Müller, L., Hübner, A., Harich, H.-D., Boller, E., Koska, M., Jänicke, M., Marschner, N., RCC-Registry Group (Tumour Registry of Advanced Renal Cell Carcinoma),… Weiterlesen